GMed's Q2 Beat Looked Strong-But 9% Base Growth and a $110M One-Time Gain Are the Real Story

The 56% EPS jump looks much better only because last year's quarter was inflated

Globus reported non-GAAP diluted EPS of $1.34, up 55.8%, but GAAP diluted earnings per share ("EPS") was $1.10, a decrease of 26.2%, primarily driven by the bargain purchase gain of $110.5 million recognized in the prior year quarter. That makes the EPS beat look far more dramatic than the underlying operating change.

A cleaner read is 6% revenue growth and 9% growth in the base business excluding Nevro. That points to a business that is still growing steadily, not one that suddenly jumped to a much higher growth tier.

Revenue guidance held steady while EPS guidance rose

Management also raised its full-year 2026 non-GAAP EPS guidance to $4.95-$5.05, up from $4.70-$4.80 while chose not to raise its full-year revenue guidance. That combination suggests margin expansion and operating leverage, not a new top-line regime.

Spine is the durable part of the story

The clearest strength is in spine. US Spine grew 7%, International Spine grew 14% as reported, and adjusted EBITDA margin expanded 740 basis points to 35.4%. US Spine also marking the fifth consecutive quarter of above-market growth.

That is the part of the business investors can underwrite with the most confidence. It is growing, it is broadening, and it is helping lift profitability.

Nevro is still the main overhang

Nevro is still weakening. Nevro sales declined 14.3% year-over-year, saw a sequential decline of $1.7 million, and management expecting trial volume recovery only by late Q4 2026. Earlier this year, management also said Nevro will probably get a little bit worse before it gets better.

That leaves the real debate intact: Globus spine looks healthy, but Nevro has not stabilized yet.

What matters next: stabilization, not another EPS headline

The next test is simple. Investors should watch for:

• a slower Nevro decline
• trends that look closer to the late-Q4 recovery timeline management outlined
• continued support for the raised its full-year 2026 non-GAAP EPS guidance to $4.95-$5.05 range

If those signals improve together, the integration narrative gets stronger. If Nevro keeps sliding while management still leans on last year's accounting backdrop, the market will likely stay focused on execution risk rather than the headline EPS beat.